AlloSure® Advances in Transplant Risk Assessment and Treatment Response
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: Newsfilter
- Evolution of Clinical Endpoint: AlloSure® is increasingly utilized in kidney, heart, and multi-organ transplantation, with data indicating its potential as a clinical endpoint for assessing treatment response and predicting graft outcomes, which may transform clinical trial designs and patient management strategies.
- Key Study Findings: In a multicenter analysis of over 4,000 kidney transplant recipients, elevated AlloSure was associated with active alloimmune injury, supporting its role as a non-invasive marker beyond conventional antibody-mediated rejection classifications, enhancing precision in risk assessment.
- New Findings in Heart Transplantation: In heart transplantation, higher AlloMap scores were significantly linked to subsequent elevations in AlloSure Heart, suggesting AlloMap as an early indicator of immune activation that may precede graft injury detection, highlighting its clinical relevance.
- Monitoring in Multiorgan Transplantation: HeartCare's routine incorporation in post-transplant follow-up for simultaneous heart-kidney transplant recipients demonstrated predictable patterns in molecular testing results, underscoring the importance of frequent non-invasive monitoring in complex transplant cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CDNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CDNA
Wall Street analysts forecast CDNA stock price to fall
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 23.480
Low
18.00
Averages
18.00
High
18.00
Current: 23.480
Low
18.00
Averages
18.00
High
18.00
About CDNA
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AlloSure® Advances in Transplant Risk Assessment and Treatment Response
- Evolution of Clinical Endpoint: AlloSure® is increasingly utilized in kidney, heart, and multi-organ transplantation, with data indicating its potential as a clinical endpoint for assessing treatment response and predicting graft outcomes, which may transform clinical trial designs and patient management strategies.
- Key Study Findings: In a multicenter analysis of over 4,000 kidney transplant recipients, elevated AlloSure was associated with active alloimmune injury, supporting its role as a non-invasive marker beyond conventional antibody-mediated rejection classifications, enhancing precision in risk assessment.
- New Findings in Heart Transplantation: In heart transplantation, higher AlloMap scores were significantly linked to subsequent elevations in AlloSure Heart, suggesting AlloMap as an early indicator of immune activation that may precede graft injury detection, highlighting its clinical relevance.
- Monitoring in Multiorgan Transplantation: HeartCare's routine incorporation in post-transplant follow-up for simultaneous heart-kidney transplant recipients demonstrated predictable patterns in molecular testing results, underscoring the importance of frequent non-invasive monitoring in complex transplant cases.
See More
CareDx Stock Surpasses Analyst Target Price
- Stock Performance: CareDx Inc (Ticker: CDNA) has surpassed the average analyst 12-month target price of $25.80, currently trading at $26.18, indicating market optimism regarding the company's future performance.
- Analyst Reactions: When a stock reaches an analyst's target price, they typically face a choice to either downgrade the valuation or raise the target price, reflecting differing views on fundamental business developments that could influence investor decisions.
- Target Price Distribution: Among analysts covered by Zacks, there is a range of target prices for CareDx, with the lowest at $21.00 and the highest at $28.00, and a standard deviation of $2.863, highlighting varying expectations for the company's future performance.
- Investor Signal: The stock's rise above the target price provides a signal for investors to reassess the company, prompting them to consider whether the current valuation is justified or if it may be prudent to take profits to mitigate risk.
See More
CareDx Shares Surge 11.5% on Positive Analysis and Earnings Outlook
- Significant Price Surge: CareDx shares rallied 11.5% in the last trading session to close at $26.18, with trading volume notably higher than typical, reflecting strong investor confidence in the company's outlook.
- Support from Analysis: The stock's rise is closely tied to the publication of the KOAR analysis in the Journal of the American Society of Nephrology, which supports the role of AlloSure Kidney as a noninvasive tool for risk stratification and clinical decision-making, boosting investor optimism.
- Strong Earnings Expectations: CareDx is expected to report quarterly earnings of $0.22 per share, representing a 120% year-over-year increase, with revenues projected at $114.35 million, up 31.9% from the previous year, indicating robust growth potential in the medical services sector.
- Increased Market Attention: Although the consensus EPS estimate has remained unchanged over the past 30 days, the stock's continued upward movement suggests heightened market interest in CareDx's future performance, prompting investors to monitor its trajectory for sustained strength.
See More
CareDx Q1 Earnings Exceed Expectations with Revenue Growth
- Earnings Beat: CareDx reported a Q1 non-GAAP EPS of $0.34, surpassing expectations by $0.21, indicating a significant improvement in profitability that boosts investor confidence.
- Significant Revenue Growth: The company achieved Q1 revenue of $117.7 million, a 39.5% year-over-year increase, exceeding market expectations by $13.25 million, demonstrating sustained competitive strength in the market.
- 2026 Revenue Guidance Raised: CareDx raised its 2026 revenue guidance to between $447 million and $465 million, surpassing the consensus estimate of $437.43 million, reflecting a positive outlook for future growth.
- Positive Stock Reaction: Following the strong earnings report, CareDx shares rose by 13%, indicating market confidence in the company's future prospects and positive investor sentiment.
See More
CareDx Reports Q2 2025 Financial Results with Strong Growth Indicators
- Financial Performance Growth: CareDx reported adjusted revenue of $90.5 million for Q2 2025, reflecting a 14% year-over-year increase, indicating strong market performance and a projected annual revenue range of $367 million to $373 million, showcasing sustained market demand and effective company strategy.
- Testing Services Expansion: The company achieved $66 million in Testing Services revenue for the second quarter, up 14% year-over-year, delivering approximately 49,500 tests, marking the eighth consecutive quarter of testing volume growth, underscoring its market leadership in monitoring heart, kidney, and lung transplants.
- New Product Launch: At the World Transplant Congress, CareDx unveiled AlloSure Plus, an AI-driven diagnostic tool that provides personalized rejection risk scores, expected to be seamlessly reported through EPIC integrations in the second half of the year, enhancing the company's competitive edge in kidney transplant monitoring.
- Policy Impact Assessment: CareDx is actively addressing the new draft LCD policy, estimating a potential $30 million annual revenue headwind if implemented, yet remains committed to driving protocol adoption to improve patient outcomes and maintain market share.
See More
CareDx (CDNA) Q2 2025 Earnings Transcript
See More
AlloSure® Advances in Transplant Risk Assessment and Treatment Response
- Evolution of Clinical Endpoint: AlloSure® is increasingly utilized in kidney, heart, and multi-organ transplantation, with data indicating its potential as a clinical endpoint for assessing treatment response and predicting graft outcomes, which may transform clinical trial designs and patient management strategies.
- Key Study Findings: In a multicenter analysis of over 4,000 kidney transplant recipients, elevated AlloSure was associated with active alloimmune injury, supporting its role as a non-invasive marker beyond conventional antibody-mediated rejection classifications, enhancing precision in risk assessment.
- New Findings in Heart Transplantation: In heart transplantation, higher AlloMap scores were significantly linked to subsequent elevations in AlloSure Heart, suggesting AlloMap as an early indicator of immune activation that may precede graft injury detection, highlighting its clinical relevance.
- Monitoring in Multiorgan Transplantation: HeartCare's routine incorporation in post-transplant follow-up for simultaneous heart-kidney transplant recipients demonstrated predictable patterns in molecular testing results, underscoring the importance of frequent non-invasive monitoring in complex transplant cases.
See More
CareDx Stock Surpasses Analyst Target Price
- Stock Performance: CareDx Inc (Ticker: CDNA) has surpassed the average analyst 12-month target price of $25.80, currently trading at $26.18, indicating market optimism regarding the company's future performance.
- Analyst Reactions: When a stock reaches an analyst's target price, they typically face a choice to either downgrade the valuation or raise the target price, reflecting differing views on fundamental business developments that could influence investor decisions.
- Target Price Distribution: Among analysts covered by Zacks, there is a range of target prices for CareDx, with the lowest at $21.00 and the highest at $28.00, and a standard deviation of $2.863, highlighting varying expectations for the company's future performance.
- Investor Signal: The stock's rise above the target price provides a signal for investors to reassess the company, prompting them to consider whether the current valuation is justified or if it may be prudent to take profits to mitigate risk.
See More
CareDx Shares Surge 11.5% on Positive Analysis and Earnings Outlook
- Significant Price Surge: CareDx shares rallied 11.5% in the last trading session to close at $26.18, with trading volume notably higher than typical, reflecting strong investor confidence in the company's outlook.
- Support from Analysis: The stock's rise is closely tied to the publication of the KOAR analysis in the Journal of the American Society of Nephrology, which supports the role of AlloSure Kidney as a noninvasive tool for risk stratification and clinical decision-making, boosting investor optimism.
- Strong Earnings Expectations: CareDx is expected to report quarterly earnings of $0.22 per share, representing a 120% year-over-year increase, with revenues projected at $114.35 million, up 31.9% from the previous year, indicating robust growth potential in the medical services sector.
- Increased Market Attention: Although the consensus EPS estimate has remained unchanged over the past 30 days, the stock's continued upward movement suggests heightened market interest in CareDx's future performance, prompting investors to monitor its trajectory for sustained strength.
See More
CareDx Q1 Earnings Exceed Expectations with Revenue Growth
- Earnings Beat: CareDx reported a Q1 non-GAAP EPS of $0.34, surpassing expectations by $0.21, indicating a significant improvement in profitability that boosts investor confidence.
- Significant Revenue Growth: The company achieved Q1 revenue of $117.7 million, a 39.5% year-over-year increase, exceeding market expectations by $13.25 million, demonstrating sustained competitive strength in the market.
- 2026 Revenue Guidance Raised: CareDx raised its 2026 revenue guidance to between $447 million and $465 million, surpassing the consensus estimate of $437.43 million, reflecting a positive outlook for future growth.
- Positive Stock Reaction: Following the strong earnings report, CareDx shares rose by 13%, indicating market confidence in the company's future prospects and positive investor sentiment.
See More
CareDx Reports Q2 2025 Financial Results with Strong Growth Indicators
- Financial Performance Growth: CareDx reported adjusted revenue of $90.5 million for Q2 2025, reflecting a 14% year-over-year increase, indicating strong market performance and a projected annual revenue range of $367 million to $373 million, showcasing sustained market demand and effective company strategy.
- Testing Services Expansion: The company achieved $66 million in Testing Services revenue for the second quarter, up 14% year-over-year, delivering approximately 49,500 tests, marking the eighth consecutive quarter of testing volume growth, underscoring its market leadership in monitoring heart, kidney, and lung transplants.
- New Product Launch: At the World Transplant Congress, CareDx unveiled AlloSure Plus, an AI-driven diagnostic tool that provides personalized rejection risk scores, expected to be seamlessly reported through EPIC integrations in the second half of the year, enhancing the company's competitive edge in kidney transplant monitoring.
- Policy Impact Assessment: CareDx is actively addressing the new draft LCD policy, estimating a potential $30 million annual revenue headwind if implemented, yet remains committed to driving protocol adoption to improve patient outcomes and maintain market share.
See More
CareDx (CDNA) Q2 2025 Earnings Transcript
See More
